Metformin and COVID-19: From cellular mechanisms to reduced mortality

por Scheen, A.J.
Publicado 2020

SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?

por Scheen, A.J.
Publicado 2020

Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports

por Scheen, A.J., Marre, M., Thivolet, C.
Publicado 2020

Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study

por De Hert, M, van Winkel, R, Van Eyck, D, Hanssens, L, Wampers, M, Scheen, A, Peuskens, J
Publicado 2006

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

por Schernthaner, G., Barnett, A. H., Betteridge, D. J., Carmena, R., Ceriello, A., Charbonnel, B., Hanefeld, M., Lehmann, R., Malecki, M. T., Nesto, R., Pirags, V., Scheen, A., Seufert, J., Sjohölm, A., Tsatsoulis, A., DeFronzo, R.
Publicado 2010

Erratum to: Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

por Schernthaner, G., Barnett, A. H., Betteridge, D. J., Carmena, R., Ceriello, A., Charbonnel, B., Hanefeld, M., Lehmann, R., Malecki, M. T., Nesto, R., Pirags, V., Scheen, A., Seufert, J., Sjöholm, Å., Tsatsoulis, A., DeFronzo, R.
Publicado 2010